|
1
|
Liang H, Yang T, Liu Z, Jian W, Chen Y, Li
B, Yan Z, Xu W, Chen L, Qi Y, et al: LungDiag: Empowering
artificial intelligence for respiratory diseases diagnosis based on
electronic health records, a multicenter study. MedComm (2020).
6:e700432025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu J, Wang J, Xiong A, Zhang L, Zhang Y,
Liu Y, Xiong Y, Li G and He X: Mitochondrial quality control in
lung diseases: Current research and future directions. Front
Physiol. 14:12366512023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Avci E, Sarvari P, Savai R, Seeger W and
Pullamsetti SS: Epigenetic mechanisms in parenchymal lung diseases:
Bystanders or therapeutic targets? Int J Mol Sci. 23:5462022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Che L, Yu C, Chen G, Lin J, Xie Z, Xia T,
Luo W, Cai X and Liu S: The inflammatory response induced by RELMβ
upregulates IL-8 and IL-1β expression in bronchial epithelial cells
in COPD. Int J Chron Obstruct Pulmon Dis. 16:2503–2513. 2021.
View Article : Google Scholar
|
|
5
|
Tralamazza SM, Gluck-Thaler E, Feurtey A
and Croll D: Copy number variation introduced by a massive mobile
element facilitates global thermal adaptation in a fungal wheat
pathogen. Nat Commun. 15:57282024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen Y, Xiao H, Liu Z, Teng F, Yang A,
Geng B, Sheng X and Xia Y: Sirt1: An increasingly interesting
molecule with a potential role in bone metabolism and osteoporosis.
Biomolecules. 14:9702024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang P, Qin D, Qin Y, Tao S and Liu G:
SIRT3/6/7: promising therapeutic targets for pulmonary fibrosis.
Front Cell Dev Biol. 13:15573842025. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grozinger CM, Chao ED, Blackwell HE,
Moazed D and Schreiber SL: Identification of a class of small
molecule inhibitors of the sirtuin family of NAD-dependent
deacetylases by phenotypic screening. J Biol Chem. 276:38837–38843.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rine J and Herskowitz I: Four genes
responsible for a position effect on expression from HML and HMR in
Saccharomyces cerevisiae. Genetics. 116:9–22. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Loo S and Rine J: Silencers and domains of
generalized repression. Science. 264:1768–1771. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Frye RA: Phylogenetic classification of
prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res
Commun. 273:793–798. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Michan S and Sinclair D: Sirtuins in
mammals: Insights into their biological function. Biochem J.
404:1–13. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Landry J, Slama JT and Sternglanz R: Role
of NAD(+) in the deacetylase activity of the SIR2-like proteins.
Biochem Biophys Res Commun. 278:685–690. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jackson MD and Denu JM: Structural
identification of 2'- and 3'-O-acetyl-ADP-ribose as novel
metabolites derived from the Sir2 family of beta -NAD+-dependent
histone/protein deacetylases. J Biol Chem. 277:18535–18544. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Anderson KA, Madsen AS, Olsen CA and
Hirschey MD: Metabolic control by sirtuins and other enzymes that
sense NAD+, NADH, or their ratio. Biochim Biophys Acta Bioenerg.
1858:991–998. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bursch KL, Goetz CJ and Smith BC: Current
trends in Sirtuin activator and inhibitor development. Molecules.
29:11852024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seto E and Yoshida M: Erasers of histone
acetylation: The histone deacetylase enzymes. Cold Spring Harb
Perspect Biol. 6:a0187132014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Houtkooper RH, Pirinen E and Auwerx J:
Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol
Cell Biol. 13:225–238. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sharma A, Mahur P, Muthukumaran J, Singh
AK and Jain M: Shedding light on structure, function and regulation
of human sirtuins: A comprehensive review. 3 Biotech. 13:292023.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vassilopoulos A, Fritz KS, Petersen DR and
Gius D: The human sirtuin family: Evolutionary divergences and
functions. Hum Genomics. 5:485–496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin L, Wei W, Jiang Y, Peng H, Cai J, Mao
C, Dai H, Choy W, Bemis JE, Jirousek MR, et al: Crystal structures
of human SIRT3 displaying substrate-induced conformational changes.
J Biol Chem. 284:24394–24405. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Michishita E, Park JY, Burneskis JM,
Barrett JC and Horikawa I: Evolutionarily conserved and
nonconserved cellular localizations and functions of human SIRT
proteins. Mol Biol Cell. 16:4623–4635. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bheda P, Jing H, Wolberger C and Lin H:
The substrate specificity of sirtuins. Annu Rev Biochem.
85:405–429. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Finkel T, Deng CX and Mostoslavsky R:
Recent progress in the biology and physiology of sirtuins. Nature.
460:587–591. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vall-Llaura N, Mir N, Garrido L, Vived C
and Cabiscol E: Redox control of yeast Sir2 activity is involved in
acetic acid resistance and longevity. Redox Biol. 24:1012292019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tanno M, Sakamoto J, Miura T, Shimamoto K
and Horio Y: Nucleocytoplasmic shuttling of the NAD+-dependent
histone deacetylase SIRT1. J Biol Chem. 282:6823–6832. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yanagisawa S, Baker JR, Vuppusetty C, Koga
T, Colley T, Fenwick P, Donnelly LE, Barnes PJ and Ito K: The
dynamic shuttling of SIRT1 between cytoplasm and nuclei in
bronchial epithelial cells by single and repeated cigarette smoke
exposure. PLoS One. 13:e01939212018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nandave M, Acharjee R, Bhaduri K, Upadhyay
J, Rupanagunta GP and Ansari MN: A pharmacological review on SIRT 1
and SIRT 2 proteins, activators, and inhibitors: Call for further
research. Int J Biol Macromol. 242:1245812023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vaquero A, Scher MB, Lee DH, Sutton A,
Cheng HL, Alt FW, Serrano L, Sternglanz R and Reinberg D: SirT2 is
a histone deacetylase with preference for histone H4 Lys 16 during
mitosis. Genes Dev. 20:1256–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Yang J, Hong T, Chen X and Cui L:
SIRT2: Controversy and multiple roles in disease and physiology.
Ageing Res Rev. 55:1009612019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Torrens-Mas M, Oliver J, Roca P and
Sastre-Serra J: SIRT3: Oncogene and tumor suppressor in cancer.
Cancers (Basel). 9:902017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang C, Liu Y, Zhu Y and Kong C: Functions
of mammalian SIRT4 in cellular metabolism and research progress in
human cancer. Oncol Lett. 20:112020.PubMed/NCBI
|
|
33
|
Nishida Y, Rardin MJ, Carrico C, He W,
Sahu AK, Gut P, Najjar R, Fitch M, Hellerstein M, Gibson BW and
Verdin E: SIRT5 regulates both cytosolic and mitochondrial protein
malonylation with glycolysis as a major target. Mol Cell.
59:321–332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang AR, Ferrer CM and Mostoslavsky R:
SIRT6, a mammalian deacylase with multitasking abilities. Physiol
Rev. 100:145–169. 2020. View Article : Google Scholar
|
|
35
|
Mostoslavsky R, Chua KF, Lombard DB, Pang
WW, Fischer MR, Gellon L, Liu P, Mostoslavsky G, Franco S, Murphy
MM, et al: Genomic instability and aging-like phenotype in the
absence of mammalian SIRT6. Cell. 124:315–329. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Emmons M, Boulware D, Sullivan DM and
Hazlehurst LA: Topoisomerase II beta levels are a determinant of
melphalan-induced DNA crosslinks and sensitivity to cell death.
Biochem Pharmacol. 72:11–18. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang J, Zhang L, Chen Y, Fang X, Li B and
Mo C: The role of cGAS-STING signaling in pulmonary fibrosis and
its therapeutic potential. Front Immunol. 14:12732482023.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Diwan R, Bhatt HN, Beaven E and Nurunnabi
M: Emerging delivery approaches for targeted pulmonary fibrosis
treatment. Adv Drug Deliv Rev. 204:1151472023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kropski JA and Blackwell TS: Progress in
understanding and treating idiopathic pulmonary fibrosis. Annu Rev
Med. 70:211–224. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huh JY, Lee JH and Song JW: Efficacy and
safety of combination therapy with pirfenidone and nintedanib in
patients with idiopathic pulmonary fibrosis. Front Pharmacol.
14:13019232023. View Article : Google Scholar
|
|
41
|
Cottin V and Maher T: Long-term clinical
and real-world experience with pirfenidone in the treatment of
idiopathic pulmonary fibrosis. Eur Respir Rev. 24:58–64. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fala L: Ofev (Nintedanib): First tyrosine
kinase inhibitor approved for the treatment of patients with
idiopathic pulmonary fibrosis. Am Health Drug Benefits. 8(Spec
Feature): 101–104. 2015.PubMed/NCBI
|
|
43
|
Mazumder S, Barman M, Bandyopadhyay U and
Bindu S: Sirtuins as endogenous regulators of lung fibrosis: A
current perspective. Life Sci. 258:1182012020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shen P, Deng X, Chen Z, Ba X, Qin K, Huang
Y, Huang Y, Li T, Yan J and Tu S: SIRT1: A potential therapeutic
target in autoimmune diseases. Front Immunol. 12:7791772021.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Avila-Carrasco L, Majano P, Sánchez-Toméro
JA, Selgas R, López-Cabrera M, Aguilera A and González Mateo G:
Natural plants compounds as modulators of epithelial-to-mesenchymal
transition. Front Pharmacol. 10:7152019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gong H, Zheng C, Lyu X, Dong L, Tan S and
Zhang X: Inhibition of Sirt2 alleviates fibroblasts activation and
pulmonary fibrosis via Smad2/3 pathway. Front Pharmacol.
12:7561312021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li N, Xiong R, Li G, Wang B and Geng Q:
PM2.5 contributed to pulmonary epithelial senescence and
ferroptosis by regulating USP3-SIRT3-P53 axis. Free Radic Biol Med.
205:291–304. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jablonski RP, Kim SJ, Cheresh P, Williams
DB, Morales-Nebreda L, Cheng Y, Yeldandi A, Bhorade S, Pardo A,
Selman M, et al: SIRT3 deficiency promotes lung fibrosis by
augmenting alveolar epithelial cell mitochondrial DNA damage and
apoptosis. FASEB J. 31:2520–2532. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cheresh P, Kim SJ, Jablonski R, Watanabe
S, Lu Z, Chi M, Helmin KA, Gius D, Budinger GRS and Kamp DW: SIRT3
overexpression ameliorates asbestos-induced pulmonary fibrosis,
mt-DNA damage, and lung fibrogenic monocyte recruitment. Int J Mol
Sci. 22:68562021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
He J, Yu C, Shen Y, Huang J, Zhou Y, Gu J,
Cao Y and Zheng Q: Sirtuin 6 ameliorates bleomycin-induced
pulmonary fibrosis via activation of lipid catabolism. J Cell
Physiol. 239:e310272024. View Article : Google Scholar
|
|
51
|
Choudhury M, Yin X, Schaefbauer KJ, Kang
JH, Roy B, Kottom TJ, Limper AH and Leof EB: SIRT7-mediated
modulation of glutaminase 1 regulates TGF-β-induced pulmonary
fibrosis. FASEB J. 34:8920–8940. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Barta JA, Powell CA and Wisnivesky JP:
Global epidemiology of lung cancer. Ann Glob Health. 85:82019.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kim J, Lee H and Huang BW: Lung cancer:
Diagnosis, treatment principles, and screening. Am Fam Physician.
105:487–494. 2022.PubMed/NCBI
|
|
56
|
Bradbury CA, Khanim FL, Hayden R, Bunce
CM, White DA, Drayson MT, Craddock C and Turner BM: Histone
deacetylases in acute myeloid leukaemia show a distinctive pattern
of expression that changes selectively in response to deacetylase
inhibitors. Leukemia. 19:1751–1759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Huffman DM, Grizzle WE, Bamman MM, Kim J,
Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated
in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang RH, Sengupta K, Li C, Kim HS, Cao L,
Xiao C, Kim S, Xu X, Zheng Y, Chilton B, et al: Impaired DNA damage
response, genome instability, and tumorigenesis in SIRT1 mutant
mice. Cancer Cell. 14:312–323. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hosseninia S, Ameli A, Aslani MR,
Pourfarzi F and Ghobadi H: Serum levels of sirtuin-1 in patients
with lung cancer and its association with karnofsky performance
status. Acta Biomed. 92:e20210122021.PubMed/NCBI
|
|
60
|
Sun L, Li H, Chen J, Dehennaut V, Zhao Y,
Yang Y, Iwasaki Y, Kahn-Perles B, Leprince D, Chen Q, et al: A
SUMOylation-dependent pathway regulates SIRT1 transcription and
lung cancer metastasis. J Natl Cancer Inst. 105:887–898. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sun L, Li H, Chen J, Iwasaki Y, Kubota T,
Matsuoka M, Shen A, Chen Q and Xu Y: PIASy mediates hypoxia-induced
SIRT1 transcriptional repression and epithelial-to-mesenchymal
transition in ovarian cancer cells. J Cell Sci. 126:3939–3947.
2013.PubMed/NCBI
|
|
62
|
Aslani MR, Matin S, Nemati A,
Mesgari-Abbasi M, Ghorbani S and Ghobadi H: Effects of conjugated
linoleic acid supplementation on serum levels of interleukin-6 and
sirtuin 1 in COPD patients. Avicenna J Phytomed. 10:305–315.
2020.PubMed/NCBI
|
|
63
|
Chen L, Mu Y and Greene WC: Acetylation of
RelA at discrete sites regulates distinct nuclear functions of
NF-kappaB. EMBO J. 21:6539–6548. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gao Z and Ye J: Inhibition of
transcriptional activity of c-JUN by SIRT1. Biochem Biophys Res
Commun. 376:793–796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Guo H, Ding H, Tang X, Liang M, Li S,
Zhang J and Cao J: Quercetin induces pro-apoptotic autophagy via
SIRT1/AMPK signaling pathway in human lung cancer cell lines A549
and H1299 in vitro. Thoracic Cancer. 12:1415–1422. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
McGlynn LM, Zino S, MacDonald AI, Curle J,
Reilly JE, Mohammed ZM, McMillan DC, Mallon E, Payne AP, Edwards J
and Shiels PG: SIRT2: Tumor suppressor or tumor promoter in
operable breast cancer? Eur J Cancer. 50:290–301. 2014. View Article : Google Scholar
|
|
67
|
Jing H, Hu J, He B, Negrón Abril YL,
Stupinski J, Weiser K, Carbonaro M, Chiang YL, Southard T,
Giannakakou P, et al: A SIRT2-Selective inhibitor promotes c-Myc
oncoprotein degradation and exhibits broad anticancer activity.
Cancer Cell. 29:767–768. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wu M, Zhang JB, Xiong YW, Zhao YX, Zheng
MG, Huang XL, Huang F, Wu XX, Li X, Fan WJ, et al: Promotion of
lung cancer metastasis by SIRT2-Mediated extracellular protein
deacetylation. Adv Sci (Weinh). 10:22054622023. View Article : Google Scholar :
|
|
69
|
Chen X, Hao B, Li D, Reiter RJ, Bai Y,
Abay B, Chen G, Lin S, Zheng T, Ren Y, et al: Melatonin inhibits
lung cancer development by reversing the Warburg effect via
stimulating the SIRT3/PDH axis. J Pineal Res. 71:e127552021.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Cao K, Chen Y, Zhao S, Huang Y, Liu T, Liu
H, Li B, Cui J, Cai J, Bai C, et al: Sirt3 promoted DNA damage
repair and radioresistance through ATM-Chk2 in non-small cell lung
cancer cells. J Cancer. 12:5464–5472. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wang X, Zeng Q, Li Z, Yang X, Xia W and
Chen Z: Adjudin synergizes with paclitaxel and inhibits cell growth
and metastasis by regulating the sirtuin 3-Forkhead box O3a axis in
human small-cell lung cancer. Thorac Cancer. 10:642–658. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Fu L, Dong Q, He J, Wang X, Xing J, Wang
E, Qiu X and Li Q: SIRT4 inhibits malignancy progression of NSCLCs,
through mitochondrial dynamics mediated by the ERK-Drp1 pathway.
Oncogene. 36:2724–2736. 2017. View Article : Google Scholar
|
|
73
|
Zhou B, Yang Y, Pang X, Shi J, Jiang T and
Zheng X: Quercetin inhibits DNA damage responses to induce
apoptosis via SIRT5/PI3K/AKT pathway in non-small cell lung cancer.
Biomed Pharmacother. 165:1150712023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Krishnamoorthy V and Vilwanathan R:
Silencing Sirtuin 6 induces cell cycle arrest and apoptosis in
non-small cell lung cancer cell lines. Genomics. 112:3703–3712.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kumari P, Tarighi S, Fuchshuber E, Li L,
Fernández-Duran I, Wang M, Ayoson J, Castelló-García JM,
Gámez-García A, Espinosa-Alcantud M, et al: SIRT7 promotes lung
cancer progression by destabilizing the tumor suppressor ARF. Proc
Natl Acad Sci USA. 121:e24092691212024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Halpin DMG, Celli BR, Criner GJ, Frith P,
López Varela MV, Salvi S, Vogelmeier CF, Chen R, Mortimer K, Montes
de Oca M, et al: The GOLD Summit on chronic obstructive pulmonary
disease in low- and middle-income countries. Int J Tuberc Lung Dis.
23:1131–1141. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Cornelius T: Clinical guideline highlights
for the hospitalist: GOLD COPD update 2024. J Hosp Med. 19:818–820.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Barnes PJ: Inflammatory endotypes in COPD.
Allergy. 74:1249–1256. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Xu J, Zeng Q, Li S, Su Q and Fan H:
Inflammation mechanism and research progress of COPD. Front
Immunol. 15:14046152024. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Li S, Huang Q and He B: SIRT1 as a
potential therapeutic target for chronic obstructive pulmonary
disease. Lung. 201:201–215. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhang L, Luo B, Ting Y, He S, Xie L and
Sun S: SIRT1 attenuates endoplasmic reticulum stress and apoptosis
in rat models of COPD. Growth Factors. 38:94–104. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang Y, Chen J, Chen W, Liu L, Dong M, Ji
J, Hu D and Zhang N: LINC00987 ameliorates COPD by regulating
LPS-Induced cell apoptosis, oxidative stress, inflammation and
autophagy through Let-7b-5p/SIRT1 axis. Int J Chron Obstruct Pulmon
Dis. 15:3213–3225. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhang M, Zhang Y, Roth M, Zhang L, Shi R,
Yang X, Li Y and Zhang J: Sirtuin 3 inhibits airway epithelial
mitochondrial oxidative stress in cigarette smoke-induced COPD.
Oxid Med Cell Longev. 2020:75829802020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Barnes PJ: Senescence in COPD and its
comorbidities. Annu Rev Physiol. 79:517–539. 2017. View Article : Google Scholar
|
|
85
|
Takasaka N, Araya J, Hara H, Ito S,
Kobayashi K, Kurita Y, Wakui H, Yoshii Y, Yumino Y, Fujii S, et al:
Autophagy induction by SIRT6 through attenuation of insulin-like
growth factor signaling is involved in the regulation of human
bronchial epithelial cell senescence. J Immunol. 192:958–968. 2014.
View Article : Google Scholar
|
|
86
|
Forgie KA, Fialka N, Freed DH and
Nagendran J: Lung transplantation, pulmonary endothelial
inflammation, and ex-situ lung perfusion: A review. Cells.
10:14172021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Laubach VE and Sharma AK: Mechanisms of
lung ischemia-reperfusion injury. Curr Opin Organ Transplant.
21:246–252. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Ferrari RS and Andrade CF: Oxidative
stress and lung ischemia-reperfusion injury. Oxid Med Cell Longev.
2015:5909872015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Haihua C, Wei W, Kun H, Yuanli L and Fei
L: Cobra venom factor-induced complement depletion protects against
lung ischemia reperfusion injury through alleviating blood-air
barrier damage. Sci Rep. 8:103462018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wu NC and Wang JJ: Niacin pretreatment
attenuates lung ischemia and reperfusion-induced pulmonary barrier
function impairment by reducing oxidative stress and activating
SIRT1 in an isolated-perfused rat lung model. Transplant Proc.
50:2834–2838. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Lu F, Wang R, Cheng Y and Li X:
Preconditioning with β-hydroxybutyrate attenuates lung
ischemia-reperfusion injury by suppressing alveolar macrophage
pyroptosis through the SIRT1-FOXO3 signaling pathway. FASEB J.
38:e700272024. View Article : Google Scholar
|
|
92
|
Yang C, Yang W, He Z, Guo J, Yang X, Wang
R and Li H: Kaempferol alleviates oxidative stress and apoptosis
through mitochondria-dependent pathway during lung
ischemia-reperfusion injury. Front Pharmacol. 12:6244022021.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhao J, Wang G, Han K, Wang Y, Wang L, Gao
J, Zhao S, Wang G, Chen S, Luo A, et al: Mitochondrial PKM2
deacetylation by procyanidin B2-induced SIRT3 upregulation
alleviates lung ischemia/reperfusion injury. Cell Death Dis.
13:5942022. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Song Z, Yan C, Zhan Y, Wang Q, Zhang Y and
Jiang T: Melatonin attenuates lung ischemia-reperfusion injury
through SIRT3 signaling-dependent mitophagy in type 2 diabetic
rats. Exp Lung Res. 49:101–115. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Jiang T, Liu Y, Meng Q, Lv X, Yue Z, Ding
W, Liu T and Cui X: Hydrogen sulfide attenuates lung
ischemia-reperfusion injury through SIRT3-dependent regulation of
mitochondrial function in type 2 diabetic rats. Surgery.
165:1014–1026. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Liu C, Pei S, Dai H, Liu Z, Ye M, Liu H,
He X, Wu S, Qin Y and Lin F: Downregulation of SIRT3 aggravates
lung ischemia reperfusion injury by increasing mitochondrial
fission and oxidative stress through HIF-1α-Dependent mechanisms.
Oxid Med Cell Longev. 2022:90419142022. View Article : Google Scholar
|
|
97
|
Meng S, Wang B and Li W: LncRNA MALAT1
improves cerebral ischemia-reperfusion injury and cognitive
dysfunction by regulating miR-142-3p/SIRT1 axis. Int J Neurosci.
133:740–753. 2023. View Article : Google Scholar
|
|
98
|
Hansen LW, Khader A, Yang WL, Prince JM,
Nicastro JM, Coppa GF and Wang P: Sirtuin 1 activator SRT1720
protects against organ injury induced by intestinal
ischemia-reperfusion. Shock. 45:359–366. 2016. View Article : Google Scholar
|
|
99
|
Liu Z, Li C, Li Y, Yu L and Qu M: Propofol
reduces renal ischemia reperfusion-mediated necroptosis by
up-regulation of SIRT1 in rats. Inflammation. 45:2038–2051. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zhang Y, Zhang H, Li S, Huang K, Jiang L
and Wang Y: Metformin alleviates LPS-induced acute lung injury by
regulating the SIRT1/NF-κB/NLRP3 pathway and inhibiting endothelial
cell pyroptosis. Front Pharmacol. 13:8013372022. View Article : Google Scholar
|
|
101
|
Chen Z, Li J, Peng H, Zhang M, Wu X, Gui
F, Li W, Ai F, Yu B and Liu Y: Meteorin-like/Meteorin-β protects
LPS-induced acute lung injury by activating SIRT1-P53-SLC7A11
mediated ferroptosis pathway. Mol Med. 29:1442023. View Article : Google Scholar
|
|
102
|
Deng S, Li J, Li L, Lin S, Yang Y, Liu T,
Zhang T, Xie G, Wu D and Xu Y: Quercetin alleviates
lipopolysaccharide-induced acute lung injury by inhibiting
ferroptosis via the Sirt1/Nrf2/Gpx4 pathway. Int J Mol Med.
52:1182023. View Article : Google Scholar
|
|
103
|
Sang A, Wang Y, Wang S, Wang Q, Wang X, Li
X and Song X: Quercetin attenuates sepsis-induced acute lung injury
via suppressing oxidative stress-mediated ER stress through
activation of SIRT1/AMPK pathways. Cell Signal. 96:1103632022.
View Article : Google Scholar
|
|
104
|
Wu Z, Wang Y, Lu S, Yin L and Dai L: SIRT3
alleviates sepsis-induced acute lung injury by inhibiting
pyroptosis via regulating the deacetylation of FoxO3a. Pulm
Pharmacol Ther. 82:1022442023. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Gao N, Liu XY, Chen J, Hu TP, Wang Y and
Zhang GQ: Menaquinone-4 alleviates sepsis-associated acute lung
injury via activating SIRT3-p53/SLC7A11 pathway. J Inflamm Res.
17:7675–7685. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Dai S, Ji J, Li R, Gao L and He X:
Stellate ganglion block attenuates LPS-Induced acute lung injury by
activating Sirt3 regulation of oxidative stress and inflammation.
Biomedicines. 12:11482024. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Xie C, Wang T, Liu A, Huang B, Zeng W, Li
Z, Peng S and Wu S: Sirt4 overexpression modulates the JAK2/STAT3
and PI3K/AKT/mTOR axes to alleviate sepsis-induced acute lung
injury. Cell Biochem Biophys. 83:1785–1798. 2025. View Article : Google Scholar
|
|
108
|
Yang J and Chen X: SIRT6 attenuates
LPS-induced inflammation and apoptosis of lung epithelial cells in
acute lung injury through ACE2/STAT3/PIM1 signaling. Immun Inflamm
Dis. 11:e8092023. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Cao Y, Peng T, Ai C, Li Z, Lei X, Li G, Li
T, Wang X and Cai S: Inhibition of SIRT6 aggravates p53-mediated
ferroptosis in acute lung injury in mice. Heliyon. 9:e222722023.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wang C, Chen Y, Cheng NT, Yang ZT, Tang HX
and Xu M: MicroRNA-762 modulates lipopolysaccharide-induced acute
lung injury via SIRT7. Immunol Invest. 51:1407–1422. 2022.
View Article : Google Scholar
|
